Bispecifics continue impressive efficacy streak, but companies look to reduce side effects: #ASH23

SAN DIEGO — Bis­pe­cif­ic an­ti­bod­ies from Re­gen­eron, John­son & John­son, Ab­b­Vie and Roche con­tin­ue to show im­pres­sive ef­fi­ca­cy in lym­phomas and myelo­ma based on new tri­al da­ta pre­sent­ed at the Amer­i­can So­ci­ety of Hema­tol­ogy’s an­nu­al meet­ing.

How­ev­er, for some agents, tox­i­c­i­ties like cy­tokine re­lease syn­drome re­main a sub­stan­tial con­cern and the FDA on Mon­day held a joint ses­sion at ASH to dis­cuss the bal­ance of ef­fi­ca­cy and safe­ty for some of the re­cent­ly ap­proved bis­pecifics that come with boxed safe­ty warn­ings.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.